Related references
Note: Only part of the references are listed.Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
Paul J. Broeckelmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era
Michael Oertel et al.
ADVANCES IN RADIATION ONCOLOGY (2023)
Treatment algorithm for patients with Hodgkin's lymphoma
Andreas Engert
ONKOLOGIE (2022)
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial
Lutz van Heek et al.
BMC CANCER (2022)
Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin's lymphoma
Niklas Benedikt Pepper et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2021)
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients
Simone de Vries et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
Peter Borchmann et al.
LANCET ONCOLOGY (2021)
Late Sequelae of Radiotherapy
Ulrike Hoeller et al.
DEUTSCHES ARZTEBLATT INTERNATIONAL (2021)
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma
David J. Cutter et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
Paul J. Broeckelmann et al.
JAMA ONCOLOGY (2020)
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group
Michael Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Anne-Segolene Cottereau et al.
BLOOD (2018)
Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines
Bouthaina Shbib Dabaja et al.
BLOOD (2018)
Quality control of involved field radiotherapy in the HD 13 and HD 14 trials
J. Kriz et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2017)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P. E. Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Peter Borchmann et al.
LANCET (2017)
Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group
Jan Kriz et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
David J. Cutter et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma
John Radford et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma
Michael Schaapveld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
David J. Cutter et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG)
Lena Specht et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Omitting Radiotherapy in Early Positron Emission Tomography-Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial
John M. M. Raemaekers et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Sarah C. Darby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PREDICTED RISK OF RADIATION-INDUCED CANCERS AFTER INVOLVED FIELD AND INVOLVED NODE RADIOTHERAPY WITH OR WITHOUT INTENSITY MODULATION FOR EARLY-STAGE HODGKIN LYMPHOMA IN FEMALE PATIENTS
Damien C. Weber et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
Hans Theodor Eich et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma:: An analysis of the German Hodgkin Study Group
Hans Theodor Eich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Involved-node radiotherapy in early-stage Hodgkin's lymphoma
Hans Theodor Eich et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2008)
Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma
David C. Hodgson et al.
CANCER (2007)
A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma -: Analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG)
Hans Theodor Eich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Late cardiotoxicity after treatment for Hodgkin lymphoma
Berthe M. P. Aleman et al.
BLOOD (2007)
Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group
HT Eich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Initiation of a teleradiotherapeutic network for patients in German lymphoma studies
HT Eich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
The HD12 panel of the German Hodgkin Lymphoma study Group (GHSG) -: A quality assurance program based on a multidisciplinary panel reviewing all patients' Imaging
HT Eich et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2004)
Long-term cause-specific mortality of patients treated for Hodgkin's disease
BMP Aleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
